Overview

Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes

Status:
Withdrawn

Trial end date:
2007-08-01

Target enrollment:
0

Participant gender:
All

Summary

This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD in adolescents. In addition, successful treatment of CFRD with repaglinide will improve nutritional status, ameliorate declines in pulmonary function, and will not have a negative impact upon quality of life.

Phase:

N/A

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Children's Hospital of Philadelphia

Treatments:

Insulin
Repaglinide

Criteria

Inclusion Criteria:

Cystic Fibrosis, Blood glucose concerning for diabetes -

Exclusion Criteria:

Known Cystic Fibrosis-Related Diabetes, Liver Disease, FEV1<40%

-